All Stories

  1. Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design
  2. Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH
  3. Therapeutic Application of mRNA for Genetic Diseases
  4. Comparative Analysis of Methods for Assessing On-Target Gene Editing Efficiencies
  5. RUNX1::RUNX1T1 Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia
  6. Nanoparticle-in-Hydrogel Delivery System for the Sequential Release of Two Drugs
  7. Lipid Nanoparticles for Nucleic Acid Delivery Beyond the Liver
  8. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
  9. Fusogenic Coiled-Coil Peptides Enhance Lipid Nanoparticle-Mediated mRNA Delivery upon Intramyocardial Administration
  10. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery
  11. Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design
  12. Natural or Synthetic RNA Delivery: A Stoichiometric Comparison of Extracellular Vesicles and Synthetic Nanoparticles
  13. Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model
  14. EVQuant; high-throughput quantification and characterization of extracellular vesicle (sub)populations
  15. Delivering the power of nanomedicine to patients today
  16. The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
  17. Local release of siRNA using polyplex-loaded thermosensitive hydrogels
  18. Drug Delivery with Extracellular Vesicles: From Imagination to Innovation
  19. A head-to-head comparison of conjugation methods for VHHs: random maleimide-thiol coupling versus controlled click chemistry
  20. Development and characterization of liposomal formulation of bortezomib
  21. Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery
  22. Thermosensitive liposomes for triggered release of cytotoxic proteins
  23. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
  24. Nanomedicines for the treatment of hematological malignancies
  25. Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety
  26. Nanomechanics of Extracellular Vesicles Reveals Vesiculation Pathways
  27. Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting
  28. Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles
  29. Squeezing for Life – Properties of Red Blood Cell Deformability
  30. Quantitative measurement of red cell surface protein expression reveals new biomarkers for hereditary spherocytosis
  31. State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery
  32. Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach
  33. Polymers and hydrogels for local nucleic acid delivery
  34. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology
  35. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis
  36. Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative
  37. Tumour-bound RNA-laden exosomes
  38. Microbubbles-Assisted Ultrasound Triggers the Release of Extracellular Vesicles
  39. Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles
  40. In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System
  41. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction
  42. Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy
  43. Polyphosphate nanoparticles on the platelet surface trigger contact system activation
  44. Clinical application of polymeric micelles for the treatment of cancer
  45. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA – an ISEV position paper
  46. Interaction of Extracellular Vesicles with Endothelial Cells Under Physiological Flow Conditions
  47. Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model
  48. ADDR editorial “Biologically-inspired drug delivery systems”
  49. Extracellular vesicles for drug delivery
  50. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment
  51. Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention
  52. Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro
  53. Cetuximab treatment alters the content of extracellular vesicles released from tumor cells
  54. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
  55. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting
  56. Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency
  57. Silencing of protease-activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice
  58. An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs
  59. In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior
  60. Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π–Π Stacking Stabilized Polymeric Micelles
  61. Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics
  62. Mechanics of Extracellular Vesicles from Red Blood Cells
  63. Extracellular Vesicles: Potential Roles in Regenerative Medicine
  64. Extracellular vesicles as drug delivery systems: Lessons from the liposome field
  65. Intercalating quaternary nicotinamide-based poly(amido amine)s for gene delivery
  66. EVpedia: a community web portal for extracellular vesicles research
  67. 448 Exposure to EGFR inhibitors influences release of extracellular vesicles by tumor cells
  68. Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease
  69. Anginex lipoplexes for delivery of anti-angiogenic siRNA
  70. Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma
  71. Hemocompatibility Assessment of two siRNA Nanocarrier Formulations
  72. Toward routine detection of extracellular vesicles in clinical samples
  73. Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation
  74. Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment
  75. Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles
  76. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles
  77. Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways
  78. Trends in polymeric delivery of nucleic acids to tumors
  79. Taxol®-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor®EL
  80. Strategies for triggered drug release from tumor targeted liposomes
  81. Red blood cell: barometer of cardiovascular health?
  82. Extracellular vesicles in the circulation: are erythrocyte microvesicles a confounder in the plasma haemoglobin assay?
  83. Oligonucleotides
  84. Red blood cell vesiculation in hereditary hemolytic anemia
  85. International Society for Extracellular Vesicles: Second Annual Meeting, 17–20 April 2013, Boston, MA (ISEV 2013)
  86. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells
  87. Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation
  88. Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles
  89. 121 Tumor-targeted Nanobullets for Anti-cancer Combination Therapy
  90. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model
  91. Drug targeting systems for inflammatory disease: One for all, all for one
  92. 1043 Novel Anti-angiogenic MiRNAs Reduce in Vivo Tumor Growth in Mouse Models
  93. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery
  94. Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis
  95. Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis
  96. Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines
  97. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles
  98. Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin α2β1 receptor
  99. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes
  100. Abstract 1112: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library
  101. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment
  102. Exosome mimetics: a novel class of drug delivery systems
  103. Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies
  104. Liposomes as carriers for colchicine-derived prodrugs: Vascular disrupting nanomedicines with tailorable drug release kinetics
  105. Polyplexes based on cationic polymers with strong nucleic acid binding properties
  106. Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery
  107. Attaching the phage display-selected GLA peptide to liposomes: Factors influencing target binding
  108. Abstract A12: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library
  109. Editorial [ Hot Topic:siRNA Based Approaches in Medicinal Chemistry and Drug Discovery (Guest Editor: Raymond M. Schiffelers )]
  110. Micro-Vesiculation and Disease, London, 13–14 September 2012
  111. Polymeric Carrier Systems for siRNA Delivery
  112. A role for activated endothelial cells in red blood cell clearance: implications for vasopathology
  113. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy
  114. Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression
  115. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: Comparison with stealth liposomes
  116. SiRNA delivery with functionalized carbon nanotubes
  117. Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors
  118. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes
  119. Physicochemical and Biological Evaluation of siRNA Polyplexes Based on PEGylated Poly(amido amine)s
  120. Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach
  121. Neovascular Age-Related Macular Degeneration
  122. Targeted Delivery of Kinase Inhibitors: A Nanomedicine Approach for Improved Selectivity in Cancer
  123. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity
  124. Gene silencing activity of siRNA polyplexes based on biodegradable polymers
  125. Optimization of poly(amido amine)s as vectors for siRNA delivery
  126. The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy
  127. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity
  128. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain
  129. Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids
  130. Disulfide-Based Poly(amido amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity
  131. Gene Silencing Activity of siRNA Polyplexes Based on Thiolated N , N , N -Trimethylated Chitosan
  132. Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental Atherosclerosis
  133. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation
  134. A method for quantifying cellular uptake of fluorescently labeled siRNA
  135. Poly(amido amine) copolymers derived from aminobutanol and ethylene diamine are excellent carriers for siRNA delivery
  136. Photochemical internalization (PCI)-mediated enhancement of gene silencing efficiency of polymethacrylates and N,N,N-trimethylated chitosan (TMC) based siRNA polyplexes
  137. Tumor vasculature as target for therapeutic intervention
  138. In Vivo Methods to Study Uptake of Nanoparticles into the Brain
  139. Liposomes targeting tumour stromal cells
  140. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin
  141. Downregulation of EGFR by a novel multivalent nanobody-liposome platform
  142. Abstract 5485: Modular nanotransporters: a chimeric multi-functional platform for drug deliveryin vivo
  143. Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability
  144. Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier
  145. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies
  146. Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
  147. Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
  148. Targeted Delivery of Anti-Inflammatory Agents to Tumors
  149. Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells
  150. Long circulating biodegradable polymeric micelles: Towards targeted drug delivery
  151. Delivery of siRNA to the Target Cell Cytoplasm: Photochemical Internalization Facilitates Endosomal Escape and Improves Silencing Efficiency, In Vitro and In Vivo
  152. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
  153. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice
  154. Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil
  155. L31 Thermosensitive and biodegradable polymeric micelles with transient stability for targeted drug delivery
  156. Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells
  157. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice
  158. Antitumor Activity of Liposomal Prednisolone Phosphate Depends on the Presence of Functional Tumor-Associated Macrophages in Tumor Tissue
  159. Therapeutic nanomedicine: Liposomal corticosteroid as targeted antiinflammatory nanomedicine
  160. Utility of Targeted Glucocorticoids in Cancer Therapy
  161. Hydrolysable core-crosslinked thermosensitive polymeric micelles: Synthesis, characterisation and in vivo studies
  162. Oligonucleotides
  163. Targeting the retinal microcirculation to treat diabetic sight problems
  164. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice
  165. Delivery of Nucleic Acids
  166. Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA
  167. Synthetic delivery systems for intravenous administration of nucleic acids
  168. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes
  169. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration
  170. Pharmaceutical Nanocarriers in Treatment and Imaging of Infection
  171. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice
  172. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy
  173. ICS-283: a system for targeted intravenous delivery of siRNA
  174. Silencing Proteins: Nanotechnological Approaches to Deliver siRNA for Cancer Therapy
  175. Targeted Delivery of siRNA
  176. Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer
  177. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis
  178. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
  179. Transporting silence: Design of carriers for siRNA to angiogenic endothelium
  180. Liposomal Targeting of Angiogenic Vasculature
  181. 318. Tumor Growth Inhibition from Tumor Targeted Delivery of Diphtheria Toxin Gene
  182. siRNA-mediated inhibition of angiogenesis
  183. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery
  184. Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice
  185. siRNA as a new drug: intellectual property
  186. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis
  187. Long-Circulating Sterically Stabilized Liposomes in the Treatment of Infections
  188. Inhibition of Ocular Angiogenesis by siRNA Targeting Vascular Endothelial Growth Factor Pathway Genes
  189. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle
  190. Pharmaceutical Prospects for RNA Interference
  191. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
  192. Innovations in liposomal formulations for antimicrobial therapy
  193. Peptide-targeted PEG-liposomes in anti-angiogenic therapy
  194. Innovations in liposomal formulations for antimicrobial therapy
  195. Biodistribution of long-circulating PEG-liposomes in a murine model of established subcutaneous abscesses
  196. Endothelial Cells at Inflammatory Sites as Target for Therapeutic Intervention
  197. LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE
  198. LIPOSOME-ENABLED SYNERGISTIC INTERACTION OF ANTIMICROBIAL AGENTS
  199. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
  200. Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin
  201. Activity of mammalian secreted phospholipase A2 from inflammatory peritoneal fluid towards PEG-liposomes. Early indications
  202. Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models
  203. Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating
  204. Targeting of Antibiotics in Bacterial Infections Using Pegylated Long-Circulating Liposomes
  205. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics
  206. Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice
  207. Diagnostic and Therapeutic Targeting of Infectious and Inflammatory Diseases Using Sterically Stabilized Liposomes
  208. Quantitative Assessment of Aortic Atherosclerosis in APOE*3 Leiden Transgenic Mice and Its Relationship to Serum Cholesterol Exposure
  209. Lipid-Based Formulations for siRNA Delivery